Susquehanna International Group
KPTI icon

Susquehanna International Group’s Karyopharm Therapeutics KPTI Stock Holding History

Susquehanna International Group’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.37M Buy
425,900
+59,600
+16% +$454K ﹤0.01% 5779
2025
Q4 		$2.7M Buy
366,300
+238,500
+187% +$1.46M ﹤0.01% 5065
2025
Q3 		$836K Buy
+127,800
New +$688K ﹤0.01% 7776
2025
Q2 		– Sell
-11,000
Closed -$41.1K – 13233
2025
Q1 		$41.1K Buy
11,000
+9,420
+596% +$80.4K ﹤0.01% 11921
2024
Q4 		$16.1K Sell
1,580
-467
-23% -$5.65K ﹤0.01% 11941
2024
Q3 		$25.5K Sell
2,047
-2,146
-51% -$26.7K ﹤0.01% 11573
2024
Q2 		$54.7K Sell
4,193
-5,354
-56% -$88.6K ﹤0.01% 11373
2024
Q1 		$216K Buy
+9,547
New +$167K ﹤0.01% 10447
2023
Q4 		– Sell
-7,267
Closed -$146K – 12863
2023
Q3 		$146K Buy
7,267
+3,427
+89% +$76.9K ﹤0.01% 10568
2023
Q2 		$103K Sell
3,840
-1,093
-22% -$47.1K ﹤0.01% 10924
2023
Q1 		$288K Sell
4,933
-8,340
-63% -$412K ﹤0.01% 9816
2022
Q4 		$677K Sell
13,273
-2,867
-18% -$199K ﹤0.01% 7107
2022
Q3 		$1.32M Buy
16,140
+1,187
+8% +$88.7K ﹤0.01% 5912
2022
Q2 		$1.01M Sell
14,953
-2,180
-13% -$200K ﹤0.01% 6509
2022
Q1 		$1.89M Sell
17,133
-314
-2% -$39.1K ﹤0.01% 5602
2021
Q4 		$1.68M Sell
17,447
-920
-5% -$91.7K ﹤0.01% 5923
2021
Q3 		$1.6M Sell
18,367
-1,226
-6% -$127K ﹤0.01% 6313
2021
Q2 		$3.03M Buy
19,593
+11,093
+131% +$1.61M ﹤0.01% 4996
2021
Q1 		$1.34M Sell
8,500
-6,753
-44% -$1.42M ﹤0.01% 6951
2020
Q4 		$3.54M Buy
15,253
+12,006
+370% +$2.78M ﹤0.01% 4024
2020
Q3 		$711K Sell
3,247
-7,880
-71% -$1.93M ﹤0.01% 6931
2020
Q2 		$3.16M Sell
11,127
-12,506
-53% -$3.7M ﹤0.01% 3715
2020
Q1 		$6.81M Buy
23,633
+5,686
+32% +$1.57M ﹤0.01% 2184
2019
Q4 		$5.16M Buy
17,947
+7,827
+77% +$1.7M ﹤0.01% 2927
2019
Q3 		$1.46M Buy
10,120
+7,087
+234% +$961K ﹤0.01% 4880
2019
Q2 		$273K Sell
3,033
-6,127
-67% -$492K ﹤0.01% 8507
2019
Q1 		$802K Buy
9,160
+5,813
+174% +$644K ﹤0.01% 5425
2018
Q4 		$470K Sell
3,347
-253
-7% -$42.7K ﹤0.01% 6143
2018
Q3 		$920K Buy
3,600
+2,627
+270% +$726K ﹤0.01% 5381
2018
Q2 		$248K Sell
973
-1,240
-56% -$307K ﹤0.01% 8201
2018
Q1 		$446K Buy
2,213
+533
+32% +$106K ﹤0.01% 6867
2017
Q4 		$242K Buy
1,680
+973
+138% +$156K ﹤0.01% 7938
2017
Q3 		$116K Sell
707
-2,540
-78% -$364K ﹤0.01% 8301
2017
Q2 		$441K Sell
3,247
-333
-9% -$49.3K ﹤0.01% 6874
2017
Q1 		$690K Buy
+3,580
New +$575K ﹤0.01% 5901
2016
Q3 		– Sell
-767
Closed -$77K – 8740
2016
Q2 		$77K Sell
767
-526
-41% -$68.3K ﹤0.01% 8133
2016
Q1 		$173K Sell
1,293
-960
-43% -$106K ﹤0.01% 8090
2015
Q4 		$448K Sell
2,253
-3,960
-64% -$857K ﹤0.01% 6973
2015
Q3 		$981K Buy
6,213
+2,566
+70% +$686K ﹤0.01% 5798
2015
Q2 		$1.49M Sell
3,647
-1,313
-26% -$568K ﹤0.01% 5349
2015
Q1 		$2.28M Buy
4,960
+2,380
+92% +$1.03M ﹤0.01% 4068
2014
Q4 		$1.45M Sell
2,580
-853
-25% -$485K ﹤0.01% 5100
2014
Q3 		$1.8M Buy
+3,433
New +$1.94M ﹤0.01% 4796

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Susquehanna International Group's KPTI Position: Q1 2026 in Review

Susquehanna International Group reduced its Karyopharm Therapeutics (KPTI) stake by 84% in Q1 2026, selling an estimated $942K and leaving 24,138 shares worth $134K. The position accounts for ﹤0.01% of the portfolio, ranked #12120.

Susquehanna International Group first reported a position in KPTI in Q4 2014 and has held it in 41 quarters since. The position peaked at $10.5M in Q2 2020. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Susquehanna International Group held 24,138 shares of Karyopharm Therapeutics worth $134K as of Q1 2026.
  • Susquehanna International Group sold 123,560 Karyopharm Therapeutics shares in Q1 2026, an estimated $942K.
  • Karyopharm Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #12120 holding.
  • Susquehanna International Group first reported a position in Karyopharm Therapeutics in Q4 2014 and has held it in 41 quarters since.
  • Susquehanna International Group's Karyopharm Therapeutics position peaked at $10.5M in Q2 2020.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.